Saturday, October 17 – Retatrutide, a next-generation GLP-1 weight-loss drug, is not yet approved for use. Nevertheless, online forums reveal that people are purchasing unapproved versions of the drug, which are not intended for human consumption, and sharing their experiences.

Friday, October 16 – Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes medications, according to new research published in The Lancet Psychiatry.

Friday, October 16 – Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss. Although the risk remains very low, Rutgers researchers say the findings warrant attention as millions of people turn to GLP-1 medications.

Thursday, October 15 – Trial finds 2 strategies to maintain weight loss results after stopping GLP-1s.

Thursday, October 15 – The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.

Thursday, October 15 – A wave of clinical trials have begun to test the ability of GLP-1 weight loss drugs to quell various substance use disorders, with some promising results. A new trial announced…

Thursday, October 15 – Doctors suggest digestive aids, protein supplements, skin care and more.

Wednesday, October 14 – Orforglipron shows weight loss benefits for both menopause and type 2 diabetes

Thursday, October 15 – (MedPage Today) — Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the FDA. (CBS News)
Meanwhile, ongoing lawsuits allege that GLP-1 receptor agonists can cause severe…

Wednesday, October 14 – (MedPage Today) — NEW ORLEANS — GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency in patients with diabetic macular edema (DME), a large retrospective cohort study showed.
Over 24 months of follow-up, “no sustained…

Wednesday, October 14 – A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.

Sunday, October 11 – Recent research shows that structured support may help with weight maintenance after stopping GLP-1s. licensed miniseries · E+/Getty

Most people regain a significant portion of the weight they lost within 1 year of stopping GLP-1 medications such as semaglutide (Wegovy) or tirzepatide (Zepbound).

A small study found that structured support, including a digital weight management app or medically tailored meals, may help slow weight regain after stopping GLP-1 medications.

Saturday, October 10 – Eli Lilly and Co. has sued an Arizona weight loss clinic and three online sellers, alleging they are illegally selling products containing the pharmaceutical giant’s investigational molecule that has not yet been approved for use in any drug, endangering consumers in a mockery of safety guidelines.

Saturday, October 10 – HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs. 

Friday, October 9 – In a new study, GLP-1 users reported nail detachment more than four times as often as nonusers. Waishaw/Getty Images

GLP-1 drugs like Ozempic have been linked to unusual nail changes in a new study.

GLP-1 users reported nail detachment more than four times as often as nonusers, and nail discoloration affected 46% of GLP-1 users, compared with 17% of nonusers.

Thursday, October 8 – A new analysis found that the diabetes medication orforglipron (Foundayo), an oral GLP-1, helped women lose weight regardless of their menopausal status. Healthline/Photo by Eli Lilly

A new analysis of previous studies found that orforglipron promoted weight loss in women regardless of their menopausal status.

This is important since the decline in estrogen after menopause can make weight loss more difficult.

Menopausal women also tend to gain weight around their midsection, which is associated with health risks.

Thursday, October 8 – Recent research shows people who switch to the Wegovy pill from a GLP-1 injection can lose additional weight. PixelsEffect · E+/Getty

People with overweight or obesity who switched from an injectable GLP-1 weight loss medication to the Wegovy (semaglutide) pill lost an average of 4.1% of their body weight over 3 months.

After 3 months, about 2 in 5 participants had lost at least 5% of their body weight.

Thursday, October 8 – Boehringer reports cardiometabolic improvements in people with t2d

Thursday, October 8 – “She definitely wasn’t the same person after starting GLP-1s.”View Entire Post ›

Thursday, October 8 – Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference and other factors—and often leads to rapid weight regain. Results from a pilot randomized trial, published in Obesity Science & Practice, suggest that structured support may attenuate early weight gain after GLP-1 cessation.

Thursday, October 8 – (MedPage Today) — Isometric exercise training — such as squats and plank exercises — was best done three times a week for short-term blood pressure (BP)-lowering benefits, a randomized study found. (BMJ Open Sport & Exercise Medicine…

Thursday, October 8 – (MedPage Today) — What menopause-related information can be tracked by wearable devices such as Apple watches? (New York Times)
GLP-1 medication prescribing surged from 2017 to 2025 among bariatric surgery-eligible teens, yet 9 out of 10 eligible…

Tuesday, September 6 – Recent research suggests that increasing your Ozempic dose may offer greater heart protection than switching to Mounjaro. Eva Kongshavn · Moment/Getty

A real-world study found that people with type 2 diabetes who increased their Ozempic dose rather than switching to Mounjaro had a lower risk of major adverse cardiovascular events (MACE).

Those who increased their Ozempic dose to 2 mg had a 6% lower risk of MACE than those who switched to Mounjaro.

Tuesday, September 6 – Exposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to the largest study of its kind, involving more than 2.1 million pregnancies and led by researchers at City St George’s.

Tuesday, October 6 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.

Sunday, October 4 – Welcome back to another edition of Endpoints Weekly! It’s October 3rd, the day he asked me what day it was. “It’s October 3rd,” I told him.

This week we had a number of prominent deals …

Saturday, October 3 – In the United Kingdom, 2.9% of patients undergoing anesthesia reported receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online Sept. 16 in Anaesthesia to coincide with the annual meeting of the Association of Anaesthetists, held Sept. 16–18 in Liverpool, England.

Saturday, October 3 – (MedPage Today) — The investigational triple agonist retatrutide substantially improved glycemic control and body weight in adults with obesity and type 2 diabetes, a phase III trial showed.
Among 1,152 participants, average percentage of body…

Saturday, October 3 – Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.

Friday, October 2 – (MedPage Today) — Users of GLP-1 receptor agonists had as much as fourfold higher likelihood for nail disorders, particularly onycholysis (separation of the fingernails or toenails), compared with patients not taking the drugs, a large prospective…

Friday, October 2 – More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.

Friday, October 2 – (MedPage Today) — An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed, but tolerability remains a concern.
Participants taking 3.6 mg and 6…

Friday, October 2 – (MedPage Today) — Starting a GLP-1 receptor agonist after giving birth is becoming more common, an analysis of claims data showed.
The percentage of women who initiated a GLP-1 medication within 6 months of delivery rose more than 20-fold, from…

Friday, October 2 – (MedPage Today) — In upstate New York, a nurse was choked with a stethoscope by a patient in the emergency room, according to police. (Syracuse.com)
A family is seeking answers after a patient fell to his death from a sixth floor window of a…

Thursday, October 1 – “Intervening in childhood could save children from decades of irreversible damage,” a transplant surgeon writes of GLP-1 weight loss drugs.

Thursday, October 1 – The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women’s Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women. The authors, that include Professor Paul Franks, Lund University, Helsingborg Hospital, Helsingborg, Sweden and Professor Claire Meek, Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK and colleagues, issue a call to action to improve the evidence based across the board for GLP-1 RA use in women worldwide.

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

Thursday, October 1 – Nail detachment is more than four times as common among people taking GLP-1 receptor agonists as among comparable people with obesity or type 2 diabetes who are not taking the drugs, according to the first controlled study to examine their potential effects on nail health.